Cargando…
Safety and Tolerability of Thrombin Inhibition in Scleroderma‐Associated Interstitial Lung Disease
OBJECTIVE: Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc) (scleroderma) and the leading cause of scleroderma‐related deaths. There exists an unmet need for a new drug therapy for ILD‐complicated SSc. Substantial evidence supports an important role for thrombin...
Autores principales: | Silver, R. M., Wilson, D. A., Akter, T., Atanelishvili, I., Huggins, J. T., Kajdasz, K., Highland, K. B., Nietert, P. J., Bogatkevich, G. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858036/ https://www.ncbi.nlm.nih.gov/pubmed/31777820 http://dx.doi.org/10.1002/acr2.11049 |
Ejemplares similares
-
The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
por: Bogatkevich, Galina S., et al.
Publicado: (2012) -
Establishment of an indirect ELISA for detection of the novel antifibrotic peptide M10
por: Akter, Tanjina, et al.
Publicado: (2017) -
D1398G Variant of MET Is Associated with Impaired Signaling of Hepatocyte Growth Factor in Alveolar Epithelial Cells and Lung Fibroblasts
por: Atanelishvili, Ilia, et al.
Publicado: (2016) -
Scleroderma-related interstitial lung disease
por: Suliman, Sally, et al.
Publicado: (2017) -
Interstitial lung disease in patients with scleroderma - Treatment with rituximab
por: Muñoz, A, et al.
Publicado: (2010)